Abstracts reviewed not cited 1-150

Abstracts that have been reviewed but not cited are included for information purposes.

1.	Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Balter M, O'Donnell D, Fitzgerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008 Feb;63(2):122-8. Epub 2007 Aug 16.
2.	Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535-40.
3.	Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006 Mar;61(3):189-95
4.	Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol 1991 Aug;31(8):714-8
5.	Anker SD, John M Pederson, Raguso C, Cicoira M, Dardai E, Laviano A, Ponikowski P, Schols AM; DGEM (German Society for Nutritional Medicine); Becker HF, Bohm M, Brunkhorst FM, Vogelmeier C; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on enteral nutrition: Cardiology and pulmonology. Clin Nutr 2006;25(2):311-8
6.	Anonymous. Varenicline effective for smoking cessation. Journal of Family Practice 2006;55(10):848-849
7.	Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med. 2006 Oct;119(10 Suppl 1):46-53.
8.	Anzueto A. Disease modification in chronic obstructive pulmonary disease. Clin Chest Med. 2007 Sep;28(3):609-16,vii.
9.	Arandjus C, Black PN, Poole PJ, Wood Baker R, Steurer-Stey C. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis. Respir Med. 2006 Oct;100(10):1671-81
10.	Aronow WS, Van Camp S, Turbow M, Whittaker K, Lurie M. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther 1979 Feb;25(2):149-53
11.	Balser E, Neher JO, Safranek S, Taraday J. Clinical inquiries: When are antibiotics indicated for acute COPD exacerbations? J Fam Pract. 2006 Dec;55(12):1079-80
12.	Bansal V, Hill K, Dolmage TE, Brooks D, Woon LJ, Goldstein RS. Modifying track layout from straight to circular has a modest effect on the 6-min walk distance. Chest. 2008 May;133(5):1155-60. Epub 2008 Feb 8.
13.	Barakat S, Michele G, George P, Nicole V, Guy A. Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(1):155-62.
14.	Baraldi E, Carraro S. Exercise testing and chronic lung diseases in children. Paediatr Respir Rev 2006;7 Suppl 1:S196-8
15.	Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, Coronell C, Gea J; ENIGMA in COPD project. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008 Feb;63(2):100-7. Epub 2007 Sep 17.
16.	Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. Respir Med. 2007 Mar;101(3):399-410. Epub 2006 Aug 17
17.	Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008 May;63(5):402-7. Epub 2008 Jan 30.
18.	Beeh KM, Beier J. Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma? Clin Exp Allergy 2006;36(2):142-157
19.	Bellamy D, Bouchard J, Henrischsen S, Johanssen G, Langhammer A, Reid J, van Weel C, Buist S. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006;15(1):48-57
20.	Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, Men Y, Powell JR, Qiu W, Ramchandani RP, Tornoe CW, Wang Y, Zheng JJ. Impact of pharmacometric reviews on new drug approval and labeling decisions—a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther. 2007 Feb;81(2):213-21.
21.	Bradley J M, Lasserson T, Elborn S, MacMahon J, O'Neill B. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD (Brief record). Chest 2007; 131(1): 278-285
22.	Braido F, Tarantini F, Ghiglione V, Melioli G, Canonica GW. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis. 2007;2(3):335-45.
23.	Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. Eur Respir J 2006;27(4):682-8
24.	Brozek Jan, Akl Elie A, Jaeschke Roman, Terrenato Irene, Cilenti Vincenzo, Cazzola Mario , Fabbri Leonardo, O'Byrne Paul, Guyatt Gordon H, Schünemann Holger. Long-acting beta2-agonists for chronic obstructive pulmonary disease: serious adverse events. Cochrane Database of Systematic Reviews: Protocols 2008 Issue 3 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007200
25.	Brubacher JR, Levine B, Hoffman RS. Intestinal pseudo-obstruction (Ogilvie's syndrome) in theophylline overdose. Vet Hum Toxicol 1996 Oct;38(5):368-70
26.	Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003 Jun;21(6):1012-6
27.	Bullen C, Whittaker R, McRobbie H, Fagerström K. A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease. Prev Cardiol. 2007 Spring;10(2 Suppl 1):5-9.
28.	Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007 Mar;12(1):23-36. Epub 2007 Mar 8
29.	Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. J Clin Pharmacol. 2007 Nov;47(11):1421-9.
30.	Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol. 2006 Nov;46(11):1234-40.
31.	Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005353.
32.	Calverley PM, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD. 2006 Dec;3(4):233-42
33.	Calvert LD, Shelley R, Singh SJ, Greenhaff PL, Bankart J, Morgan MD, Steiner MC. Dichloroacetate enhances performance and reduces blood lactate during maximal cycle exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 May 15;177(10):1090-4. Epub 2008 Feb 8.
34.	Candy B, Taylor SJ, Ramsay J, Esmond G, Griffiths CJ, Bryar RM. Service implications from a comparison of the evidence on the effectiveness and a survey of provision in England and Wales of COPD specialist nurse services in the community. Int J Nurs Stud. 2007 May;44(4):601-10. Epub 2006 Feb 28
35.	Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007 May;32(5):912-23. Epub 2006 Jul 27.
36.	Cappelleri JC, Baker CL, Bushmakin AG, Reeves K. Effect of varenicline on reinforcing effects associated with smoking (POS1-118). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida 2006:70
37.	Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. Curr Med Res Opin. 2005 May;21(5):749-60.
38.	Casanova C, Baudet JS, del Valle Velasco M, Martin JM, Aguirre-Jaime A, de Torres JP, Celli BR. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004 Jun;23(6):841-5
39.	Cecins N, Geelhoed E, Jenkins SC. Reduction in hospitalisation following pulmonary rehabilitation in patients with COPD. Aust Health Rev. 2008 Aug;32(3):415-22.
40.	Celli BR. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thoracic Soc 2006;3(1):58-65
41.	Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8. Epub 2008 May 29.
42.	Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2007 Apr 18(2):CD006316
43.	Chen YH, Yao WZ, Cai BQ, Wang H, Deng XM, Gao HL, Huang JS, Wang XM. Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J (Engl). 2008 Apr 5;121(7):587-91.
44.	Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474-7.
45.	Cofta-Woerpel L, Wright KL, Wetter DW. Smoking cessation 1: pharmacological treatments. Behav Med. 2006 Summer;32(2):47-56.
46.	Cofta-Woerpel L, Wright KL, Wetter DW. Smoking cessation 3: multicomponent interventions. Behav Med. 2007 Winter;32(4):135-49.
47.	Cohen L, Kitzes R, Shnaider H. Multifocal atrial tachycardia responsive to parenteral magnesium. Magnes Res 1988 Dec;1(3-4):239-42
48.	Corelli RL, Hudmon KS. Pharmacologic interventions for smoking cessation. Crit Care Nurs Clin North Am. 2006 Mar;18(1):39-51, xii.
49.	Cornuz J. Smoking cessation interventions in clinical practice. Eur J Vasc Endovasc Surg. 2007 Oct;34(4):397-404. Epub 2007 Aug 3.
50.	Cornuz J. Treating tobacco use and dependence in clinical practice. Expert Opin Pharmacother. 2006 Apr;7(6):783-92.
51.	Coventry PA, Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. J Psychosom Res. 2007 Nov;63(5):551-65.
52.	Coxson HO, Quiney B, Sin DD, Xing L, McWilliams AM, Mayo JR, Lam S. Airway wall thickness assessed using computed tomography and optical coherence tomography. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1201-6. Epub 2008 Feb 28.
53.	Cranston JM, Crockett AJ, Moss JR, Pegram RW, Stocks NP. Models of chronic disease management in primary care for patients with mild-to-moderate asthma or COPD: a narrative review. Med J Aust. 2008 Apr 21;188(8 Suppl):S50-2.
54.	Criner GJ, Sharafkhaneh A, Player R, Conoscenti CS, Johnson P, Keyser MT, Cassino C. Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD. 2008 Feb;5(1):35-41.
55.	Crockett A J, Cranston J M, Moss J R, Alpers J H. A review of long-term oxygen therapy for chronic obstructive pulmonary disease (Brief record). Respiratory Medicine 2001; 95(6): 437-443
56.	Croghan E. Optimizing on smoke free legislation making the most of the opportunity. Br J Community Nurs. 2007 Aug;12(8):334-6.
57.	Cummings KM, Mahoney M. Current and emerging treatment approaches for tobacco dependence. Curr Oncol Rep. 2006 Nov;8(6):475-83.
58.	Curtis JR, Cook DJ, Sinuff T, White DB, Hill N, Keenan SP, Benditt JO, Kacmarek R, Kirchhoff KT, Levy MM; Society of Critical Care Medicine Palliative Noninvasive Positive VentilationTask Force. Noninvasive positive pressure ventilation in critical and palliative care settings: understanding the goals of therapy. Crit Care Med. 2007 Mar;35(3):932-9
59.	D’Souza AO, Smith MJ, Miller LJ, Kavookjian J. An appraisal of pharmacoeconomic evidence of maintenance therapy in COPD. Chest 2006;129(6):1693-708
60.	deRuiter W, Faulkner G. Tobacco harm reduction strategies: the case for physical activity. Nicotine Tob Res. 2006 Apr;8(2):157-68.
61.	Doggrell SA. Which is the best primary medication for long-term smoking cessation—nicotine replacement therapy, bupropion or varenicline? Expert Opin Pharmacother. 2007 Dec;8(17):2903-15.
62.	Dolmage TE, Goldstein RS. Effects of one-legged exercise training of patients with COPD. Chest. 2008 Feb;133(2):370-6. Epub 2007 Oct 9.
63.	Donner CF. Acute exacerbation of chronic bronchitis: need for an evidence-based approach. Pulm Pharmacol Ther. 2006;19 Suppl 1:4-10. Epub 2005 Dec 15
64.	Duck A. Cost-effectiveness and efficacy in long-term oxygen therapy. Nurs Times. 2006 Feb 14-20;102(7):46-50
65.	Durham L, Hancock HC. Critical care outreach 2: uncovering the underpinning philosophy and knowledge through collaborative reflection. Nurs Crit Care. 2006 Sep-Oct;11(5):248-59
66.	Eastham KM, Hammal DM, Parker L, Spencer DA. A follow-up study of children hospitalised with community-acquired pneumonia. Arch Dis Child. 2008 Sep;93(9):755-9. Epub 2008 Apr 1.
67.	Ebbert JO, Sood A, Hays JT, Dale LC, Hurt RD. Treating tobacco dependence: review of the best and latest treatment options. J Thorac Oncol. 2007 Mar;2(3):249-56.
68.	Eisner MD, Blanc PD, Yelin EH, Sidney S, Katz PP, Ackerson L, Lathon P, Tolstykh I, Omachi T, Byl N, Iribarren C. COPD as a systemic disease: impact on physical functional limitations. Am J Med. 2008 Sep;121(9):789-96.
69.	Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control. 2006 Aug;15(4):280-5.
70.	Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol. 2006 Dec;46(12):1439-48.
71.	Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol. 2006 Sep;46(9):991-8.
72.	The FDA approves new drug for smoking cessation. FDA Consum. 2006 Jul-Aug;40(4):29.
73.	Ferreira I M, Brooks D, Lacasse Y, Goldstein R S. Nutritional intervention in COPD: a systematic overview (Brief record). Chest 2001; 119(2): 353-363
74.	Ferreira I M, Brooks D, Lacasse Y, Goldstein R S. Nutritional support for individuals with COPD: a meta-analysis (Brief record). Chest 2000; 117(3): 672-678
75.	Foreman MG, Willsie SK. Health care disparities in critical illness. Clin Chest Med. 2006 Sep;27(3):473-86, vii
76.	Foronjy R, Wallace A, D'Armiento J. The pharmokinetic limitations of antioxidant treatment for COPD. Pulm Pharmacol Ther. 2008;21(2):370-9. Epub 2007 Oct 23.
77.	Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006 May;60(5):571-6.
78.	Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006;7:74
79.	Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet. 2008 Sep 20;372(9643):1088-99.
80.	Frishman WH, Mitta W, Kupersmith A, Ky T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev. 2006 Mar-Apr;14(2):57-73.
81.	Frishman WH. Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. Prev Cardiol. 2007 Spring;10(2 Suppl 1):10-22.
82.	Fromer L, Cooper CB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract. 2008 Aug;62(8):1219-36. Epub 2008 Jun 28.
83.	Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4(3):253-62
84.	Garwood CL, Potts LA. Emerging pharmacotherapies for smoking cessation. Am J Health Syst Pharm. 2007 Aug 15;64(16):1693-8.
85.	Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar;15(3):307-15.
86.	Giudici MC, Gumpert TJ, Heathman LL. Narrow-complex tachycardia. Am Fam Physician 1994 Mar;49(4):823-34
87.	Glover ED, Rath JM. Varenicline: progress in smoking cessation treatment. Expert Opin Pharmacother. 2007 Aug;8(11):1757-67.
88.	Gonzales DH, Rennard SI, Billing CB, Reeves KR, Watsky E, Gong J. A pooled analysis of varenicline, and alpha 4 beta 2 nicotinic receptor partial agonist vs bupropion for smoking cessation (PA9-2). Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida 2006:32
89.	Gonzales D, Swartz S, Oncken C, Wang H, Reeves K, Gong J, Watsky E, Williams K. Quitting patterns during 12 weeks of treatment for smoking cessation with varenicline: results from a pooled-analysis of varenicline vs bupropion or placebo (PA11-2). Society for Research on Nicotine and Tobacco 13th Annual Meeting February 21-24, Austin, Texas 2007: 32
90.	Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA : the journal of the American Medical Association 2006; 296(1):47-55
91.	Granizo JJ, Gimenez MJ, Barberan J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther. 2006 Dec;28(12):2061-9
92.	Grgic A, Wilkens H, Kubale R, Gröschel A, Buecker A, Sybrecht GW. Low-dose MDCT for surveillance of patients with severe homogeneous emphysema after bronchoscopic airway bypass. AJR Am J Roentgenol. 2008 Sep;191(3):W112-9.
93.	Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax. 2007 Jun 15; [Epub ahead of print]
94.	Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 2006;28(2):330-8
95.	Halbert RJ, Isonaka S. International Primary Care Respiratory Group (IPCRG) Guidelines: integrating diagnostic guidelines for managing chronic respiratory diseases in primary care. Prim Care Respir J 2006;15(1):13-19
96.	Hallberg J, Dominicus A, Eriksson UK, Gerhardsson de Verdier M, Pedersen NL, Dahlbäck M, Nihlén U, Higenbottam T, Svartengren M. Interaction between smoking and genetic factors in the development of chronic bronchitis. Am J Respir Crit Care Med. 2008 Mar 1;177(5):486-90. Epub 2007 Nov 29.
97.	Hanania NA. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007 Oct;29(10):2121-33.
98.	Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb;5(1):25-34.
99.	Harris M, Smith B, Veale A, Esterman A, Frith P, Selim P. Informed consumers as drivers of evidence based medicine: a trial. X111 International Cochrane Colloquium. October 2005, Melbourne. (Oral presentation) http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/1205
100.	Harris M, Wildgoose D, Veale A, Smith B. Patient mediated interventions to increase adoption of evidence: aids and barriers to an intervention in chronic obstructive pulmonary disease (COPD). X111 International Cochrane Colloquium. October 2005, Melbourne. (Oral presentation) http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/1206
101.	Hasanoglu HC, Yildirim Z, Hasanoglu A, Ozcan C, Gokirmak M, Koksal N, Kalkan S. Effects of ranitidine on pulmonary function tests of patients with chronic obstructive pulmonary disease. Pharmacol Res 2003 Jun;47(6):535-9
102.	Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7.
103.	Hurford WE, Cheifetz IM. Respiratory controversies in the critical care setting. Should heliox be used for mechanically ventilated patients? Respir Care. 2007 May;52(5):582-91; discussion 591-4
104.	Hughes JR. Measurement of the effects of abstinence from tobacco: a qualitative review. Psychol Addict Behav. 2007 Jun;21(2):127-37.
105.	Incorvaia C, Riario-Sforza GG, Pravettoni C, Yacoub MR, Frati F. Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium. Int J Chron Obstruct Pulmon Dis. 2008;3(1):123-6.
106.	Jackson KC 2nd, Nahoopii R, Said Q, Dirani R, Brixner D. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med. 2007 Apr;49(4):453-60
107.	Jarvis H. Exploring the evidence base of the use of non-invasive ventilation. Br J Nurs. 2006 Jul 27-Aug 9;15(14):756-9
108.	Jónsdóttir H. Nursing care in the chronic phase of COPD: a call for innovative disciplinary research. J Clin Nurs. 2008 Apr;17(7B):272-90.
109.	Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63.
110.	Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007 Mar-Apr;29(2):147-55
111.	Kawayama T, Hoshino T, Ichiki M, Tsuda T, Kinoshita M, Takata S, Koga T, Iwanaga T, Aizawa H; Kurume COPD Study Group. Effect of add-on therapy of tiotropium in COPD treated with theophylline. Int J Chron Obstruct Pulmon Dis. 2008;3(1):137-47.
112.	Keating RJ, Gersh BJ, Hodge DO, Weivoda PL, Patel PJ, Hammill SC, Shen WK. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol 2005 Nov 15;96(10):1420-4
113.	Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs. 2006;20(11):945-60
114.	Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3(1):127-36.
115.	Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J. 2007 Aug;30(2):293-306. Epub 2007 Apr 25
116.	Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol. 2007 Feb;102(2):412-29; quiz 468
117.	Kothari SA, Apiyasawat S, Asad N, Spodick DH. Evidence supporting a new rate threshold for multifocal atrial tachycardia. Clin Cardiol 2005 Dec;28(12):561-3
118.	Kumar D, Saksena RK. Best evidence topic report. Use of Heliox in the management of acute exacerbation of COPD. Emerg Med J. 2007 Jan;24(1):45-8
119.	Kuralay E, Cingoz F, Kilic S, Bolcal C, Gunay C, Demirkilic U, Tatar H. Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg 2004 Feb;25(2):224-30
120.	Lacasse Y, Martin S, Lasserson TJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease: a Cochrane systematic review (Brief record). Europa Medicophysica 2007;43(4):475-485
121.	Lam CY, Minnix JA, Robinson JD, Cinciripini PM. A brief review of pharmacotherapies for smoking cessation. J Natl Compr Canc Netw. 2006 Jul;4(6):583-9.
122.	Lam S, Patel PN. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev. 2007 May-Jun;15(3):154-61.
123.	Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008 Feb 15;177(4):396-401. Epub 2007 Nov 29.
124.	Laviolette L, Bourbeau J, Bernard S, Lacasse Y, Pepin V, Breton MJ, Baltzan M, Rouleau M, Maltais F. Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax. 2008 Feb;63(2):115-21. Epub 2007 Sep 27.
125.	Leeman RF, Huffman CJ, O'Malley SS. Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. Alcohol Alcohol. 2007 May-Jun;42(3):196-206.
126.	Le Foll B, George TP. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ. 2007 Nov 20;177(11):1373-80.
127.	Lightowler J V, Wedzicha J A, Elliott M W, Ram F S. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis (Brief record). BMJ 2003; 326:185-187
128.	Lopez CM, House-Fancher MA. Management of atrial fibrillation in patients with chronic obstructive pulmonary disease. J Cardiovasc Nurs 2005 Mar-Apr;20(2):133-40
129.	Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration. 2007;74(4):411-7. Epub 2006 Sep 5
130.	Luker KA, Chalmers KI, Caress AL, Salmon MP. Smoking cessation interventions in chronic obstructive pulmonary disease and the role of the family: a systematic literature review. J Adv Nurs. 2007 Sep;59(6):559-68
131.	Lusuardi M, Garuti G, Massobrio M, Spagnolatti L, Bendinelli S. Heart and lungs in COPD. Close friends in real life--separate in daily medical practice? Monaldi Arch Chest Dis. 2008 Mar;69(1):11-7.
132.	Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006;130:640-646
133.	MacIntyre NR. Corticosteroid therapy and chronic obstructive pulmonary disease. Respir Care 2006;51(3):289-96
134.	Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs. 2007 Nov;16(11):1775-83.
135.	McCord JK, Borzak S, Davis T, Gheorghiade M. Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease. Am J Cardiol 1998 Jan 1;81(1):91-3
136.	McCrory DC, Brown C, Gray RN, Goslin RE, Kolimaga JT, MacIntyre NR, Oddone EZ, Matchar DB. Management of acute exacerbations of chronic obstructive pulmonary disease (Structured Abstract) 2001:256
137.	Meyer P, Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 2006 Jul 26;24(31-32):5832-8
138.	Minakata Y, Iijima H, Takahashi T, Miura M, Ogawa H, Kimura K, Koga T, Kinoshita M, Tsuda T, Aizawa H, Ichinose M. Efficacy and safety of formoterol in Japanese patients with COPD. Intern Med. 2008;47(4):217-23. Epub 2008 Feb 15.
139.	Minami S, Kawayama T, Ichiki M, Nishiyama M, Sueyasu Y, Gohara R, Kinoshita M, Koga H, Iwanaga T, Aizawa H. Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline. Intern Med. 2008;47(6):503-9. Epub 2008 Mar 17.
140.	Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother. 2008 Jul;9(10):1755-72.
141.	Mitrouska I, Bouloukaki I, Siafakas NM. Pharmacological approaches to smoking cessation. Pulm Pharmacol Ther. 2007;20(3):220-32. Epub 2006 Feb 23.
142.	Mojon P. Oral health and respiratory infection. J Can Dent Assoc 2002;68(6):340-5
143.	Mokhlesi B. Clinical implications of gastroesophageal reflux disease and swallowing dysfunction in COPD. Am J Respir Med 2003;2(2):117-21
144.	Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006 Jul;6(7):965-81.
145.	Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology. 2008 Jun-Jul;59(3):357-64. Epub 2008 Apr 2.
146.	Myers T. The value of care algorithms. Pharmacotherapy. 2006 Sep;26(9 Pt 2):181S-91S; discussion 191S-92S
147.	Nides M, Leischow S, Sarna L, Evans SE. Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions. Prev Cardiol. 2007 Spring;10(2 Suppl 1):23-30.
148.	NIH State-of-the-Science Conference Statement on Tobacco Use: Prevention, Cessation, and Control. NIH Consens State Sci Statements. 2006 Jun 12-14;23(3):1-26.
149.	Nishimura K, Oga T, Ikeda A, Hajiro T, Tsukino M, Koyama H. Comparison of health-related quality of life measurements using a single value in patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2008 Sep;45(7):615-20.
150.	Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc. 2007 May;82(5):575-82

< Prev		Next >